Your browser doesn't support javascript.
loading
Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States.
Rencsok, Emily M; Slopen, Natalie; McManus, Hannah D; Autio, Karen A; Morgans, Alicia K; McSwain, Lawrence; Barata, Pedro; Cheng, Heather H; Dreicer, Robert; Gerke, Travis; Green, Rebecca; Heath, Elisabeth I; Howard, Lauren E; McKay, Rana R; Nowak, Joel; Pileggi, Shannon; Pomerantz, Mark M; Rathkopf, Dana E; Tagawa, Scott T; Whang, Young E; Ragin, Camille; Odedina, Folakemi T; Kantoff, Philip W; Vinson, Jake; Villanti, Paul; Haneuse, Sebastien; Mucci, Lorelei A; George, Daniel J.
Affiliation
  • Rencsok EM; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Slopen N; Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts.
  • McManus HD; Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Autio KA; Duke Cancer Institute, Durham, North Carolina.
  • Morgans AK; Memorial Sloan Kettering Cancer Center, New York, New York.
  • McSwain L; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Barata P; Patient author, Durham, North Carolina.
  • Cheng HH; Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana.
  • Dreicer R; University Hospitals Seidman Cancer Center, Cleveland, Ohio.
  • Gerke T; Division of Medical Oncology, University of Washington, Seattle, Washington.
  • Green R; Fred Hutchinson Cancer Center, Seattle, Washington.
  • Heath EI; University of Virginia Cancer Center, Charlottesville, Virginia.
  • Howard LE; Prostate Cancer Clinical Trials Consortium (PCCTC), New York, New York.
  • McKay RR; Prostate Cancer Clinical Trials Consortium (PCCTC), New York, New York.
  • Nowak J; Karmanos Cancer Institute, Detroit, Michigan.
  • Pileggi S; Duke Cancer Institute, Durham, North Carolina.
  • Pomerantz MM; Department of Oncology, University of California San Diego Moores Cancer Center, La Jolla, California.
  • Rathkopf DE; Patient author, Durham, North Carolina.
  • Tagawa ST; Cancer ABCs, Brooklyn, New York.
  • Whang YE; Prostate Cancer Clinical Trials Consortium (PCCTC), New York, New York.
  • Ragin C; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Odedina FT; Memorial Sloan Kettering Cancer Center, New York, New York.
  • Kantoff PW; Division of Hematology and Medical Oncology, Weill Cornell Medical Center, New York, New York.
  • Vinson J; Department of Medicine, Division of Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
  • Villanti P; Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Haneuse S; African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania.
  • Mucci LA; Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
  • George DJ; Prostate Cancer Transatlantic Consortium (CaPTC), Jacksonville, Florida.
Cancer Res Commun ; 4(1): 55-64, 2024 01 08.
Article in En | MEDLINE | ID: mdl-38108490
ABSTRACT
Bone pain is a well-known quality-of-life detriment for individuals with prostate cancer and is associated with survival. This study expands previous work into racial differences in multiple patient-reported dimensions of pain and the association between baseline and longitudinal pain and mortality. This is a prospective cohort study of individuals with newly diagnosed advanced prostate cancer enrolled in the International Registry for Men with Advanced Prostate Cancer (IRONMAN) from 2017 to 2023 at U.S. sites. Differences in four pain scores at study enrollment by race were investigated. Cox proportional hazards models and joint longitudinal survival models were fit for each of the scale scores to estimate HRs and 95% confidence intervals (CI) for the association with all-cause mortality. The cohort included 879 individuals (20% self-identifying as Black) enrolled at 38 U.S. sites. Black participants had worse pain at baseline compared with White participants, most notably a higher average pain rating (mean 3.1 vs. 2.2 on a 10-point scale). For each pain scale, higher pain was associated with higher mortality after adjusting for measures of disease burden, particularly for severe bone pain compared with no pain (HR, 2.47; 95% CI 1.44-4.22). The association between pain and all-cause mortality was stronger for participants with castration-resistant prostate cancer compared with those with metastatic hormone-sensitive prostate cancer and was similar among Black and White participants. Overall, Black participants reported worse pain than White participants, and more severe pain was associated with higher mortality independent of clinical covariates for all pain scales.

SIGNIFICANCE:

Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse survival. More holistic clinical assessments of pain in this population are needed to determine the factors upon which to intervene to improve quality of life and survivorship, particularly for Black individuals.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Cancer Pain Limits: Humans / Male Country/Region as subject: America do norte Language: En Journal: Cancer Res Commun Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms / Cancer Pain Limits: Humans / Male Country/Region as subject: America do norte Language: En Journal: Cancer Res Commun Year: 2024 Type: Article